华兰生物：公司点评报告：贝伐珠单抗获批上市

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][6] Core Views - The company has received approval for its product Bevacizumab injection, branded as "Anbeiyou," which is primarily used for treating various types of cancer [4][5] - The sales of Bevacizumab in China reached approximately 10.68 billion yuan in 2023, reflecting a growth of 23.71% compared to 2022, indicating potential revenue growth for the company [5] - The company maintains its earnings forecast for 2024-2026, with expected earnings per share of 0.73 yuan, 0.89 yuan, and 1.03 yuan respectively, corresponding to price-to-earnings ratios of 23.89, 19.44, and 16.87 [6] Financial Data Summary - As of September 30, 2024, the company reported a closing price of 17.39 yuan, with a market capitalization of 27.367 billion yuan [2] - The company’s net profit for 2023 is projected to be 1.762 billion yuan, with a growth rate of 37.66% compared to 2022 [7] - The company’s revenue for 2024 is estimated at 5.366 billion yuan, showing a slight increase of 0.45% from 2023 [7] - The gross profit margin is reported at 61.77%, and the return on equity is 7.90% [2][7]